Legal & General Group
RVNC

Legal & General Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Legal & General Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-110,199
Closed -$335K – 3400
2024
Q4 		$335K Buy
110,199
+4,726
+4% +$20.6K ﹤0.01% 2587
2024
Q3 		$547K Buy
105,473
+40,429
+62% +$201K ﹤0.01% 2433
2024
Q2 		$167K Sell
65,044
-18,128
-22% -$61.9K ﹤0.01% 2687
2024
Q1 		$409K Sell
83,172
-291
-0.3% -$1.72K ﹤0.01% 2505
2023
Q4 		$734K Buy
83,463
+163
+0.2% +$1.33K ﹤0.01% 2317
2023
Q3 		$955K Buy
83,300
+5,382
+7% +$103K ﹤0.01% 2205
2023
Q2 		$1.97M Buy
77,918
+35,541
+84% +$1.11M ﹤0.01% 1939
2023
Q1 		$1.36M Buy
42,377
+7,635
+22% +$238K ﹤0.01% 2042
2022
Q4 		$641K Buy
34,742
+1,717
+5% +$39.3K ﹤0.01% 2275
2022
Q3 		$891K Sell
33,025
-8,594
-21% -$174K ﹤0.01% 2178
2022
Q2 		$575K Sell
41,619
-281
-0.7% -$4.33K ﹤0.01% 2309
2022
Q1 		$817K Buy
41,900
+538
+1% +$8.16K ﹤0.01% 2281
2021
Q4 		$675K Buy
41,362
+9,187
+29% +$153K ﹤0.01% 2333
2021
Q3 		$896K Buy
32,175
+13,296
+70% +$379K ﹤0.01% 2270
2021
Q2 		$560K Buy
18,879
+625
+3% +$18K ﹤0.01% 2320
2021
Q1 		$510K Buy
18,254
+1,164
+7% +$32.2K ﹤0.01% 2302
2020
Q4 		$484K Sell
17,090
-1,004
-6% -$26K ﹤0.01% 2271
2020
Q3 		$455K Sell
18,094
-1,777
-9% -$46.6K ﹤0.01% 2221
2020
Q2 		$485K Buy
19,871
+807
+4% +$15.9K ﹤0.01% 2177
2020
Q1 		$283K Buy
19,064
+738
+4% +$15.3K ﹤0.01% 2208
2019
Q4 		$298K Buy
18,326
+8,294
+83% +$129K ﹤0.01% 2315
2019
Q3 		$130K Buy
10,032
+1,411
+16% +$17.3K ﹤0.01% 2452
2019
Q2 		$112K Buy
8,621
+1,008
+13% +$12.7K ﹤0.01% 2493
2019
Q1 		$120K Buy
7,613
+1,168
+18% +$20.3K ﹤0.01% 2442
2018
Q4 		$130K Buy
6,445
+1,150
+22% +$25.3K ﹤0.01% 2402
2018
Q3 		$131K Hold
5,295
– – ﹤0.01% 2436
2018
Q2 		$145K Buy
5,295
+127
+2% +$3.82K ﹤0.01% 2376
2018
Q1 		$159K Sell
5,168
-638
-11% -$20.5K ﹤0.01% 2356
2017
Q4 		$209K Hold
5,806
– – ﹤0.01% 2302
2017
Q3 		$159K Sell
5,806
-9
-0.2% -$218 ﹤0.01% 2422
2017
Q2 		$152K Buy
5,815
+438
+8% +$9.77K ﹤0.01% 2404
2017
Q1 		$110K Sell
5,377
-60
-1% -$1.23K ﹤0.01% 2489
2016
Q4 		$113K Buy
5,437
+1,876
+53% +$31.4K ﹤0.01% 2490
2016
Q3 		$58K Hold
3,561
– – ﹤0.01% 2448
2016
Q2 		$49K Hold
3,561
– – ﹤0.01% 2488
2016
Q1 		$63K Buy
3,561
+1,000
+39% +$20.4K ﹤0.01% 2313
2015
Q4 		$91K Hold
2,561
– – ﹤0.01% 2132
2015
Q3 		$73K Buy
2,561
+773
+43% +$23.5K ﹤0.01% 2226
2015
Q2 		$58K Buy
1,788
+835
+88% +$21.5K ﹤0.01% 2475
2015
Q1 		$19K Hold
953
– – ﹤0.01% 2729
2014
Q4 		$16K Hold
953
– – ﹤0.01% 2646
2014
Q3 		$19K Buy
+953
New +$24.8K ﹤0.01% 2615

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Legal & General Group's RVNC Position: Q1 2025 in Review

Legal & General Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 110,199 shares — an estimated $335K sold.

Legal & General Group first reported a position in RVNC in Q3 2014 and held it in 42 quarters. The position peaked at $1.97M in Q2 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Legal & General Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Legal & General Group sold 110,199 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $335K.
  • Legal & General Group first reported a position in Revance Therapeutics, Inc. in Q3 2014 and held it in 42 quarters.
  • Legal & General Group's Revance Therapeutics, Inc. position peaked at $1.97M in Q2 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Legal & General Group's 13F filing for Q1 2025, filed 15 May 2025.